ATI Musculoskeletal System / Musculoskeletal ATI System |Verified and 100% Correct Q & A, Complete Document for ATI Exam|

Musculoskeletal System
1. A HCP should tell a pts ho is taking alendronate (Fosamax) to monitor for which of the
following adverse effects?
A. Jaw Pain (osteonecrosis of jaw)
B. Blurred vision (ocular inflammation)
C. Muscle pain (if analgesics don’t help, may discontinue)
2. A HCP is caring for a pt who is to begin taking calcitonin-salmon (Miacalcin) intranasal
spray to treat osteoporosis. Which of the following information should the HCP include?
A. Report rash or itching (discontinue and seek medical attention)
B. Prime the pump (ensure proper dosage)
C. Report nasal irritation (may need parenteral administration)
3. A HCP is caring for a pt who is taking a calcium supplement and reports flank pain. The
HCP should suspect the pt has which of the following? Renal calculi (increase water
intake; report blood in urine or flank pain)
4. A HCP is caring for a pt who is taking raloxifene (Evista). Which of the following




m
er as
information should the HCP include?
A. Increase activity, such as walking (prevent DVTs, increase bone density)




co
eH w
B. Use a contraceptive if there is any risk of pregnancy (category X)
C. Increase intake of calcium and vitamin D (improve effectiveness and increase




o.
bone mass)
rs e
5. A HCP is caring for a pt who is about to begin methotrexate therapy for RA. The HCP
ou urc
should include which of the following information?
A. Avoid people who are sick (bone marrow suppression, increases risk for
infection)
o

B. Periodic laboratory tests are essential (monitor for kidney and liver damage)
aC s


C. Report bruising or petechiae (thrombocytopenia)
vi y re



D. Avoid drinking alcohol (increases risk of liver damage)
6. A HCP is caring for a pt who is taking alendronate (Fosamax) to treat postmenopausal
osteoporosis. The HCP should explain to the pt that alendronate increases bone mass by
ed d




which of the following actions? Decreases activity of osteoclasts (reduces bone
resorption)
ar stu




7. A HCP is preparing to administer neostigmine (Prostigmin) to a pt who has myasthenia
gravis. Knowing the adverse effects of neostigmine, which of the following drugs should
the HCP have ready to administer? Atropine (AtroPen, reverse bradycardia)
is




8. A HCP should tell a pt who is taking etanercept (Enbrel) for RA to report which of the
Th




following? Skin rash (Steven-Johnson syndrome, toxic epidermal necrolysis)
9. A HCP should tell a pt who is taking methotrexate to monitor for which of the following?
Black, tarry stools (gastric intestinal ulceration  perforation and bleeding)
10. A HCP is preparing to administer alendronate (Fosamax) to a pt who has osteoporosis.
sh




The HCP should recognize which of the following as an adverse effect of alendronate?
Joint pain (treat with analgesics)
11. A HCP is caring for a pts ho is taking etanercept (Enbrel), a DMARD II that treats RA.
The HCP should monitor the pt for which of the following indications of a servious
adverse reaction to the drug? Shortness of breath (heart failure)



This study source was downloaded by 100000827662005 from CourseHero.com on 10-30-2021 10:09:31 GMT -05:00


https://www.coursehero.com/file/26708937/ATI-Musculoskeletal-Systemdocx/